201 – 210 of 304
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
(
- Contribution to journal › Article
-
Mark
Concentrations of Metals, beta-Amyloid and Tau-Markers in Cerebrospinal Fluid in Patients with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Cholinesterase Inhibitor Treated Naturalistic Alzheimer Patients.
2009) 9th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)(
- Contribution to conference › Poster
-
Mark
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
(
- Contribution to journal › Article
-
Mark
Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
The PPAR-alpha gene in Alzheimer's disease: Lack of replication of earlier association
(
- Contribution to journal › Article
-
Mark
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
2009) 13th Congress of the European-Federation-of-Neurological-Societies In European Journal of Neurology 16(Suppl 3). p.337-337(
- Contribution to journal › Published meeting abstract
-
Mark
Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk
(
- Contribution to journal › Article